7 Jul 2021 07:00
07 July 2021
Diurnal Group plc
("Diurnal" or the "Company")
Notice of Full Year Results and Adoption of Financial Reporting Standard ("FRS") 101
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the year ended 30 June 2021 on Tuesday, 14 September 2021.
Diurnal Group plc has elected to adopt FRS 101, Reduced Disclosure Framework, under the UK Generally Accepted Accounting Practice ("GAAP") accounting framework for the preparation of its parent and UK subsidiary company financial statements for the year ended 30 June 2021 and on an ongoing basis until such time as shareholders are notified of any change, primarily to reduce duplicated disclosures in its UK subsidiary company financial statements. Diurnal Group plc's election to adopt FRS 101 for its parent and UK subsidiary company financial statements does not require shareholder approval. However, as stipulated in FRS 101, Diurnal is required to notify all shareholders of this election. Any shareholder or shareholders holding in aggregate 5% or more of the total allotted shares in Diurnal Group plc may serve an objection to the use of the disclosure exemptions. Objections must be served in writing and delivered to the Company Secretary at Diurnal Group plc, Cardiff Medicentre, Heath Park, Cardiff, CF14 4UJ, UK, no later than one month from the date of this announcement.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker) | +44 (0)20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: Rupert Dearden | |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Alex Davis | |
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk